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Cigarette smoking is an important risk factor for bladder cancer
(Cluade et al, 1986; Jensen et al, 1987; Augustine et al, 1988;
Schairer et al, 1988; Burch et al, 1989; Lopez-Abente et al, 1991).
Cigarette smoke includes 2-naphthylamine and 4-aminobiphenyl,
which are recognized as human and animal carcinogens
(International Agency for Research on Cancer, 1986).
The N-acetyltransferase (NAT) has two isozymes, NAT1 and
NAT2. Each gene is located on chromosome 8 and has an open
reading frame of 870-base pair. The enzyme activities of NAT1
and NAT2 are polymorphic (Grant et al, 1992; Weber and Vatsis,
1993; Bell et al, 1995a). NAT1 gene has sequence polymorphism
in the 3¢ untranslated region, the known alleles include NAT1*4
(wild-type), NAT1*10, NAT1*11 and NAT1*3 (Vatsis and Weber,
1993). NAT2 gene has a number of point mutations, which result
in decreased NAT activity. The four mutations are NAT2*5 (C at
nucleotide 341), NAT2*6 (A at nucleotide 590), NAT2*7 (A at
nucleotide 857) and NAT2*14 (A at nucleotide 191) (Vatsis et al,
1995). NAT1*10 allele may increase enzyme activity and two
NAT2 mutant alleles may decrease enzyme activity (Hickman and
Sim, 1991; Vineis et al, 1994; Bell et al, 1995a). Both NAT1 and
NAT2 enzymes catalyse the N-acetylation of aromatic amine
which is considered a detoxifying process. NAT1 also catalyses
the  O-acetylation forming N-hydroxyarylamines and converts
arylhydroxamic acids into mutagenic acetoxy esters by N,O-
acetyltransferase reaction (Hein et al, 1992; Bartsch et al, 1993;
Skipper and Tannenbaum, 1994).
While NAT2 slow acetylators were found to have an increased
risk of bladder cancer among cigarette smokers (Risch et al, 1995;
Brockmoller et al, 1996), there were inconsistent findings
regarding the effect of NAT1 genetic polymorphism on bladder
cancer (Okkels et al, 1997; Taylor et al, 1998). The specific aim of
this study is to examine the effects of NAT1 and NAT2 on cigarette




In this case control study, 74 patients affected with urinary bladder
cancer were serially recruited from National Taiwan University
Hospital. All of them were diagnosed histologically to be affected
with transitional cell carcinoma. A total of 184 control subjects
within the same age range of cases were recruited from health
examination clinic (77.8%) and urology clinic (22.2%) in the same
hospital. They were not affected with any cancer. Subjects who
had lived in the arseniasis-endemic area were excluded from this
study. The proportion of males was 78.4% for cases and 77.7% for
controls. Cases and controls had similar frequency for distribution
of age. There were 44.6% cases and 54.3% controls with an age
below 65 years old. Because there were insufficient male elderly
subjects to be selected as controls from the health examination
clinic, several male controls were recruited from the urology clinic
among patients with benign prostatic hypertrophy. Benign
prostatic hypertrophy is a very common condition among elderly
males in Taiwan, and no association between NAT and benign
prostatic hypertrophy has ever been documented.
Standardized personal interview based on a structured question-
naire was carried out to collect information on risk factors,
including sociodemographic characteristics, residential and occu-
pational history, habits of cigarette smoking and consumption of
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Correspondence to: C-J Chenalcohol, tea and coffee, dietary habits, personal and family history
of urinary disease and cancers. Duration and quantity of cigarette
smoking was inquired in detail. Subjects who had smoked
cigarettes more than 3 days a week for more than 6 months were
classified as cigarette smokers and the others as non-smokers. A
peripheral blood sample was collected from each subject using
disposable vacuum syringe containing heparin. DNA was
extracted from peripheral lymphocytes by Genomix DNA extrac-
tion kit (Talent, Follatoio, Italy) resuspended in deionized distilled
water, and stored at –20°C until genotyping.
Genotypes of NAT1 and NAT2
NAT1 was amplified by polymerase chain reaction (PCR) using
the primers N1-OA (5¢-GCTCACCAGTTATCAACTGAC) and
N1-OB (5¢-AACCAACATTAAAAGCTTTCT) and resulted in a
233-base pair amplificate. The PCR mixture was composed of
1000–2000 ng DNA, 20 pmole of each NAT1 primers, 1 U Taq
polymerase (Takara Taq, Takara Shuzo, Japan), 5 ml 10 ´ PCR
buffer (100 mM Tris–HCl (pH 8.3), 500 mM potassium chloride
(KCl), 15 mM magnesium chloride (MgCl2)) and 4 ml 2.5 mM
deoxynucleoside triphosphates in a final volume of 50 ml. The
reaction mixture was placed for 5 min at 94°C, and then subjected
to 30 cycles of 94°C for 30 s, 52°C for 30 s and 72°C for 45 s. This
was followed by a final step at 72°C for 10 min. Negative control
was included in each set of PCR analyses. The PCR products were
electrophoresed in 1.5% agarose gel (FMC, Rockland, ME, USA)
and then extracted the DNA by QIAquick gel extraction kit
(QIAGEN, Germany). The product was processed with a Taq-dye
terminator cycle sequencing ready reaction kit (Applied
Biosystems Inc., Foster City, CA, USA). The fragments were then
analysed with an Applied Biosystems 373A automated sequencer
with a denaturing 6% polyacrylamide gel.
For NAT2, a PCR was carried out with PCR primers N5
(5¢-GGAACAAATTGGACTTGG) and N4 (5¢-TCTAGCAT-
GAATCACTCTGC). The PCR mixture was composed of
1000–2000 ng DNA, 50 pmol of each primer, 5 U Taq polymerase
(Takara Taq, Takara Shuzo, Japan), 5 ml 10 ´ PCR buffer 100 mM
Tris–HCl (pH 8.3), 500 mM KCl, 15 mM MgCl2 and 4 ml 2.5 mM
deoxynucleoside triphosphates in a final volume of 50 ml. It was
denatured at 94°C for 5 min and subjected to 35 cycles of 94°C for
30 s, 52°C for 30 s and 72°C for 90 s. A final 72°C extension for
10 min was performed. The whole intronless NAT2 gene was
resulted in a 1093-base pair amplificate. It was then digested with
5U   KpnI (AGS Gmbh, Germany) for NAT2*5 fragment,
10 U  BamHI (AGS Gmbh, Germany) for NAT2*7 fragment and
5U   AluI/MspI (Boehringer Mannheim, Germany) for NAT2*14
fragment at 37°C overnight, respectively, and 5 U TaqI
(Boehringer Mannheim, Germany) for NAT2*6 at 65°C overnight.
The NAT2*5, NAT2*7 and NAT2*14 fragments were separated in
2% agarose gel, and NAT2*6 fragments in 3% agarose gel.
Individuals with two mutant alleles including NAT2*5, NAT2*6,
NAT2*7 or NAT2*14 (Vatsis et al, 1995) were classified as slow
acetylators and the others were rapid acetylators.
Statistical analysis
The differences in frequency distributions of bladder cancer risk
factors between cases and controls were tested for their statistical
significance by c2 tests. In the univariate analysis, odds ratios
(OR) with a 95% confidence interval (CI) for each risk factor were
calculated after the adjustment for age (continuous variable), sex
and educational level (categorized variable) through logistic
regression analysis. Cases had a slightly older mean age at recruit-
ment, and lower educational levels than controls.
RESULTS
While fewer cases (10%) than controls (20%) were habitual coffee
drinkers, there was no significant association between coffee
drinking and bladder cancer after adjustment for age, sex and
educational level (OR = 0.6, 95% CI = 0.2–1.4). The proportions
of habitual alcohol drinking were 30% for cases and 24% for
controls, a multivariate-adjusted OR of 1.1 (95% CI 0.6–2.2).
Forty-five per cent cases and 48% controls were tea drinkers with
a multivariate-adjusted OR of 0.9 (95% CI 0.5–1.7). Few study
subjects had well documented occupational exposures related to
bladder cancer. Only one case and one control were engaged in
printing and painting industry, and three cases and two controls
were professional drivers. The consumption of coffee, alcohol and
tea, as well as the above occupational exposures, were not con-
sidered as confounding factors.
Table 1 compares the cigarette smoking habit between bladder
cancer cases and healthy controls. Cases had a higher percentage
of cigarette smokers than controls (0.05 < P < 0.10) showing an
OR of developing bladder cancer of 1.90 (95% CI 0.99–3.64) after
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Table 1 Comparison of cigarette smoking habit between bladder cancer cases and healthy controls
Cases Controls Adjusted odds ratioa
Cigarette smoking Group No. (%) No. (%) (95% CI)
Habit No 35 (47.3) 119 (64.7) 1.00 (referent)
Yes 39 (52.7) 65 (35.3) 1.91 (0.99–3.64)d
Duration (year)b 0 35 (49.3) 119 (66.5) 1.00 (referent)
<33 12 (16.9) 27 (15.1) 1.41 (0.58–3.42)
³33 24 (33.8) 33 (18.4) 2.52 (1.16–5.50)c
Quantity (packs per day)b 0 35 (47.9) 119 (65.7) 1.00 (referent)
<1 18 (24.7) 36 (19.9) 1.76 (0.82–3.78)
³1 20 (27.4) 26 (14.4) 2.35 (1.05–5.24)c
aAdjustment for age, sex and educational level through logistic regression analysis. bDuration and/or quantity of
cigarette consumption were not available for three cases and six controls cP < 0.05 bases on the significance test of
the odds ratio. d0.05 < P < 0.10 bases on the significance test of the odds ratio. eP < 0.05 bases on the trend test. 
CI: confidence interval.adjustment for age, sex and educational level. There were signifi-
cant dose–response relationships between the risk of bladder
cancer and the duration and quantity of cigarette smoking.
The frequency distributions of NAT1 and NAT2 alleles and
genotypes in cases and controls are compared in Table 2. Cases
and controls had similar allele frequency distributions of NAT1
and NAT2. A total of 61.5% cases and 64.9% controls had one or
two alleles of NAT1*10; 20.6% cases and 24.0% controls were
NAT2 slow acetylators. The genotype frequency distributions of
NAT1 and NAT2 were alike in cases and controls. The combined
frequency distribution of NAT1 and NAT2 was also similar in
cases and controls.
As shown in Table 3, the OR of developing bladder cancer for
cigarette smoking was further analysed by stratifying study
subjects according to NAT1 and NAT2 genotypes. Among cases,
those subjects carrying NAT1*10 allele and NAT2 slow acetyla-
tors had an increased bladder cancer risk associated with cigarette
smoking, they were classified as one group to be compared with
cases with NAT2 rapid acetylators and without NAT1*10 allele as
another group. A significant association between bladder cancer
and cigarette smoking was observed among subjects carrying
NAT1*10 allele or NAT2 slow acetylators showing an OR of 2.34
(95% CI 1.03–5.31), but not among NAT2 rapid acetylators
without NAT1*10 allele (OR 2.07, 95% CI 0.32–13.30). The
dose–response relationships between the risk of bladder cancer
and the quantity and duration of cigarette smoking were also statis-
tically significant among those who had NAT1*10 allele or NAT2
slow acetylators, but not for cases with NAT2 rapid acetylators but
without NAT1*10 allele.
DISCUSSION
As in previous studies of cigarette smoking and bladder cancer, we
also observed an increased risk of bladder cancer among cigarette
smokers in this study. The metabolism of carcinogenic arylamines
in tobacco smoke is mediated by enzymes including NAT1 and
NAT2. Both NAT1 and NAT2 are genotypically and pheno-
typically polymorphic with variable genotype frequencies in
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Table 2 Comparison of NAT 1 and NAT 2 allele and genotype frequency between cases of bladder cancer
and controls
Cases Controls
Gene Allele/Genotype No. (%) No. (%) P-valuea
NAT1b *3 4 (3.1) 11 (3.2) 0.92
*4 75 (57.7) 186 (54.4)
*10 50 (38.5) 143 (41.8)
*11 1 (0.7) 2 (0.6)
NAT2b NAT2*4 (wild) 85 (58.2) 192 (52.6) 0.70
NAT2*5 6 (4.1) 22 (6.0)
NAT2*6 33 (22.6) 99 (27.0)
NAT2*7 21 (14.4) 51 (13.9)
NAT2*14 1 (0.7) 2 (0.5)
NAT1 Without *10 25 (38.5) 60 (35.1) 0.63
With *10 40 (61.5) 111 (64.9)
NAT2 Slow acetylator 15 (20.6) 44 (24.0) 0.55
Rapid acetylator 58 (79.4) 139 (76.0)
NAT1/NAT2 Without *10/slow 6 (9.4) 18 (10.6) 0.53
Without *10/rapid 18 (28.1) 42 (24.7)
With *10/slow 5 (7.8) 25 (14.7)
With *10/rapid 35 (54.7) 85 (50.0)
aBased on c2 test. bNAT1 genotypes were not available for nine cases and 13 controls, while NAT2
genotypes were not available for one case and one control.
Table 3 Association between cigarette smoking and bladder cancer risk stratified by genotypes of NAT1 and NAT2
Adjusted odds ratio (95% confidence interval)a
Cigarette smoking Group NAT2 rapid acetylator With NAT1 *10 or
Without NAT1 *10 NAT2 slow acetylator
Habit No 1.00 (referent) 1.00 (referent)
Yes 2.07 (0.32–13.30) 2.34 (1.03–5.31)b
Duration (year) 0 1.00 (referent) 1.00 (referent)
<33 0.55 (0.04–7.83) 1.78 (0.58–5.45)b
³33 4.33 (0.56–33.41) 3.08 (1.14–8.32)b,c
Quantity (pack/day) 0 1.00 (referent) 1.00 (referent)
<1 2.65 (0.34–20.70) 2.13 (0.82–5.53)
³1 1.49 (0.16–13.93) 3.22 (1.17–8.86)b,c
aAdjustment for age, sex and educational level through logistic regression analysis. bP < 0.05 based on the
significance test of the odds ratio. cP < 0.05 based on the trend test.different ethnic groups. The allele frequency of NAT1*10 in
controls of this study was 41.8%, which is significantly higher (c2
= 4.00, P < 0.05) than the 30.0% observed in Caucasians (Bell et
al, 1995b). The frequency of NAT2 slow acetylator in controls of
this study was 24.0%, which is similar to that observed among
Chinese in Hong Kong (27.0%) (Lin et al, 1993) and lower than
that among American Caucasians (55.0%) (Bell et al, 1993). The
percentage of NAT2 slow acetylator is significantly lower in
Taiwanese than in American Caucasians (c2 = 20.14, P < 0.001).
NAT2 slow acetylators were found to have an increased risk of
bladder cancer among cigarette smokers (Risch et al, 1995;
Brockmoller et al, 1996). The NAT1*10 allele alone was reported
to be a risk factor in one study (Taylor et al, 1998), but not in
another (Okkels et al, 1997). In this study, the genetic polymor-
phism of neither NAT1 nor NAT2 was significantly associated
with the development of bladder cancer. However, the significant
dose–response relationships between cigarette smoking and
bladder cancer were observed in this study among those with
NAT1*10 or NAT2 slow acetylators, but not among NAT2 rapid
acetylators without NAT1*10 allele.
Some aromatic amines are metabolically inactivated through
acetylation in the liver mainly by NAT2 (Kadlubar and Badawi,
1995). Rapid NAT2 acetylators are considered to have a higher
level of non-toxic metabolites and a lower risk of bladder can-
cer than slow NAT2 acetylators. Some other arylamines were
catalysed by cytochrome P450 1A2 in the liver, and the N-hydroxy
arylamine metabolites can then enter the blood stream. The
N-hydroxy arylamine metabolites are further metabolized into
highly electrophilic N-acetoxy derivatives by NAT1, which is
expressed mainly in urinary bladder epithelium (Kirlin et al, 1989;
Frederickson et al, 1994). This will lead to an elevated level of
arylamine-DNA adducts and an increased risk of bladder cancer.
The dose–response relationship between cigarette smoking and
bladder cancer is thus significant among cigarette smokers who
have NAT1*10 allele and/or cigarette-smoking NAT2 slow
acetylators.
In addition to NAT1 and NAT2, the metabolism of arylamines
also involves a number of other enzymes including sulpho-
transferases (Kato and Yamazoe, 1994), prostaglandin H synthase
(Smith et al, 1992), cytochrome P450 1A2 (Butler et al, 1989;
Fleming et al, 1994) and glucuronyltransferases. These enzymes
may also contribute to the metabolic steps of arylamines relevant
to the development of bladder cancer. Further examination of
effects of these enzymes on the cigarette smoking-related bladder
cancer in humans is noteworthy.
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